Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Rating Upgraded by Mizuho

Mizuho upgraded shares of Corvus Pharmaceuticals (NASDAQ:CRVS - Free Report) from a hold rating to a strong-buy rating in a report issued on Tuesday morning, Zacks.com reports.

A number of other research firms have also recently issued reports on CRVS. StockNews.com upgraded Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday. LADENBURG THALM/SH SH lifted their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a "buy" rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $10.83.

Corvus Pharmaceuticals Stock Up 1.6 %

Shares of CRVS traded up $0.12 on Tuesday, hitting $7.68. The company's stock had a trading volume of 1,309,144 shares, compared to its average volume of 312,190. The firm's fifty day moving average price is $5.33 and its 200-day moving average price is $3.23. Corvus Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $8.33. The firm has a market capitalization of $480.39 million, a price-to-earnings ratio of -14.77 and a beta of 1.14.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.05. During the same quarter in the prior year, the business posted ($0.14) earnings per share. As a group, equities analysts predict that Corvus Pharmaceuticals will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of large investors have recently modified their holdings of CRVS. Avity Investment Management Inc. raised its holdings in Corvus Pharmaceuticals by 138.2% during the third quarter. Avity Investment Management Inc. now owns 27,580 shares of the company's stock worth $146,000 after acquiring an additional 16,000 shares in the last quarter. Towerview LLC boosted its holdings in shares of Corvus Pharmaceuticals by 4.6% in the 2nd quarter. Towerview LLC now owns 400,000 shares of the company's stock valued at $728,000 after buying an additional 17,500 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at $44,000. Marshall Wace LLP bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at $136,000. Finally, Vanguard Group Inc. increased its holdings in Corvus Pharmaceuticals by 10.6% during the first quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company's stock worth $2,658,000 after buying an additional 142,724 shares during the last quarter. 46.64% of the stock is currently owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.